Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose
(MTD), pharmacokinetics, and pharmacodynamics of the combination of WX-UK1 and capecitabine
in patients with advanced malignancies.